Abcam plc Anno IPO

Cos'è Anno IPO di Abcam plc?

Anno IPO di Abcam plc è 1998

Qual è la definizione di Anno IPO?

L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.

Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.

Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.

The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.

Anno IPO di aziende nel Health Care settore su LSE rispetto a Abcam plc

Cosa fa Abcam plc?

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; cell line and lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. It also sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Aziende con anno ipo simili a Abcam plc